Navigation Links
Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009
Date:9/15/2009

s and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal qua
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s ... stay competitive in the semiconductor, clean room and ... impact product quality and productivity, according to Dwight ... in 1980 in Lewisville, TX, Leatherwood Plastics ... left the business. Much of Leatherwood’s equipment building ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SeqLL ... Sequencing (tSMS™) technology, announced today the closing of ... investment, led by Genomic Diagnostic Technologies, will increase ... diagnostic applications. , Founded in March 2013 by ... Bioinformatics Analyst at Helicos BioSciences, SeqLL has continued ...
(Date:9/18/2014)... at USC have developed a new microscopy technology ... living animals at higher-than-ever resolution. , Dubbed "Complementation ... imaging resolutions that are an order of magnitude ... into the behavior of biomolecules at the nanometer ... 18 by Nature Communications , the researchers ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
(Date:9/17/2014)... Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical ... identified 5 genes differentially expressed in normal accompanying ... could be used to classify colorectal tumors, predict ... appropriate clinical decisions to prevent relapses. , ... most common in our population considering both sexes. ...
(Date:9/17/2014)... decades of decline, grasses have returned to some once-denuded ... marsh in those places seems healthy again, but a ... the marsh coastal protection remains diminished. , ... hasn,t come back," said ecologist Mark Bertness, professor of ... in the journal Biological Conservation . "The metric ...
(Date:9/17/2014)... including MRSA and MSSA could be curbed by ... the scaly surface of shark skin, according to ... Antimicrobial Resistance and Infection Control . , The ... spread of human disease bacteria through touching, sneezes ... arrangement of ridges formulated to resemble shark skin. ...
Breaking Biology News(10 mins):Five genes to predict colorectal cancer relapses 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Sharks' skin has teeth in the fight against hospital superbugs 2
... of a shift in U.S. demographics and importance of ... how do those growing toward majority acquire representation in ... that mentor and move minorities forward to majorities in ... that is gaining traction, said Castillo-Chavez, one of a ...
... Bunions bothering you? How about lower back pain, or impacted ... millennia to walk on two legs, grow larger brains and ... experienced some negative consequences on our way to becoming the ... But keeping our evolutionary history in mind can help us ...
... simultaneously to that which is visible and can be subjectively ... hunger is known as ,hidden hunger, or chronic malnutrition. Every ... hidden hunger before they are five years old. Year ... of starvation, which is responsible for the deaths of millions ...
Cached Biology News:Mentoring models to move minorities to majorities in STEM 2Mentoring models to move minorities to majorities in STEM 3Is there a Neanderthal in the house? 2Malnutrition -- Living hungrily ever after 2
... (phospho Y1007) ( Abpromise for ... Antigen: Synthesized phosphopeptide derived from ... of tyrosine 1007 (K-E-Y P -Y-K). ... 3717 Swiss ...
... Perm Buffer III is ... fixation of PBMCs (or ... staining for intracellular kinases ... simultaneously. Applications: Intracellular ...
Cytofix/Cytoperm Kit 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Biology Products: